Previous close | 1.1600 |
Open | 1.1600 |
Bid | 0.0000 |
Ask | 2.2500 |
Strike | 2.50 |
Expiry date | 2024-11-15 |
Day's range | 1.1600 - 1.1600 |
Contract range | N/A |
Volume | |
Open interest | 11 |
Eton Pharmaceuticals ( NASDAQ:ETON ) First Quarter 2024 Results Key Financial Results Revenue: US$7.97m (up 50% from 1Q...
Q1 2024 Eton Pharmaceuticals Inc Earnings Call
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali